AKRX


Akorn, Inc. (ARKX) Shares Up on Rumor It’s a Takeover Target; The Company Confirms

Akorn, Inc. (NASDAQ:AKRX) investors are overwhelmingly excited today following an earlier report from Bloomberg, claiming that European health-care provider Kabi Fresenius is considering a bid …

Akorn, Inc. (AKRX) Announces 3Q:16 Financial Results; Shares Tumble 10%

Akorn, Inc. (NASDAQ:AKRX) announced its financial results for the third quarter of 2016.

Akorn, Inc. (AKRX) Provides First Quarter 2016 Results; Revenue Grew 18% Over Last Year’s Frst Quarter

Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, today provided first quarter 2016 financial results.

Stock Update (NASDAQ:AKRX): Akorn, Inc. Completes 2014 Financial Statement Restatement and Reports Audited 2015 and Restated 2014 Results

Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, today announced that it has filed its Annual Report on Form 10-K for the fiscal …

Analysts Weigh In on Two Volatile Stocks: Akorn, Inc. (AKRX), G-III Apparel Group, Ltd. (GIII)

Analysts are weighing in on drug maker Akorn, Inc. (NASDAQ:AKRX) and clothes maker G-III Apparel Group, Ltd.

Stock Update (NASDAQ:AKRX): Akorn, Inc. Provides Preliminary Unaudited Full Year 2015 Financial Results And Issues 2016 Financial Guidance

Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, today provided preliminary unaudited 2015 financial results and issued 2016 financial guidance.

Company Update (NASDAQ:AKRX): Akorn, Inc. Appoints Greg Lawless as Chief Human Resources Officer

Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, today announced that Gregory P.

Stock Update (NASDAQ:AKRX): Akorn, Inc. Launches Buprenorphine/Naloxone Sublingual Tablets and Tobramycin Injection

Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched Buprenorphine and Naloxone Sublingual Tablets CIII in 2mg/0.